Trial Profile
An Open-Label Study Using the Medpulser Electroporation System to Treat Head and Neck Cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2017
Price :
$35
*
At a glance
- Drugs Bleomycin (Primary)
- Indications Head and neck cancer
- Focus Registrational; Therapeutic Use
- Sponsors Inovio Pharmaceuticals
- 23 Apr 2012 Interim results from 81 patients have been presented at the 5th European Conference on Head and Neck Oncology according to an OncoSec Medical media release.
- 26 Sep 2011 Primary endpoint 'Locoregional-control' has been met, as reported in an OncoSec Medical media release.
- 26 Sep 2011 Positive interim results reported in an OncoSec Medical media release.